Crystalline Forms of Sufentanil
The present invention provides crystalline forms of sufentanil citrate and methods for preparing crystalline forms of sufentanil citrate.
1 . A crystalline form of sufentanil citrate, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]4-piperidinyl]-N-phenylpropanamide, 2-hydroxy-1,2,3-propanetricarboxylate, wherein the crystalline form is hydrous Form II.
2 . The crystalline form of claim 1 , wherein the crystalline form exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 5.6, about 10.0, about 11.4, about 13.4, about 19.1, and about 21.2.
3 . The crystalline form of claim 1 , wherein the crystalline form exhibits an endothermic transition with an onset of about 114°-118° C. as measured by differential scanning calorimetry.
4 . The crystalline form of claim 1 , wherein the crystalline form comprises no more than about 5% by weight of crystalline Form I.
5 . A pharmaceutical composition, comprising:
a) Form II crystalline form of sufentanil citrate, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]4-piperidinyl]-N-phenylpropanamide, 2-hydroxy-1,2,3-propanetricarboxylate; and
b) a pharmaceutically acceptable excipient.
6 . The pharmaceutical composition of claim 5 , wherein the crystalline Form II exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 5.6, about 10.0, about 11.4, about 13.4, about 19.1, and about 21.2.
7 . The pharmaceutical composition of claim 5 , wherein the crystalline Form II exhibits an endothermic transition with an onset of about 114°-118° C. as measured by differential scanning calorimetry.
8 . The pharmaceutical composition of claim 5 , wherein the crystalline form comprises no more than about 5% by weight of crystalline Form I.
9 . A process for preparing a substantially pure anhydrous crystalline Form I of sufentanil citrate, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, 2-hydroxy-1,2,3-propanetricarboxylate, the process comprising:
a) contacting sufentanil citrate, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, 2-hydroxy-1,2,3-propanetricarboxylate, with a solvent to form a saturated or a near saturated solution; and
b) forming crystals of substantially pure anhydrous crystalline Form I.
10 . The process of claim 9 , wherein the crystals are formed by slow evaporation of the solvent.
11 . The process of claim 9 , wherein the saturated or near saturated solution is heated to about the boiling point of the solvent during step (a).
12 . The process of claim 11 , wherein the crystals are formed by cooling the solution.
13 . The process of claim 9 , further comprising the step of collecting the crystals of substantially pure crystalline Form I.
14 . The process of claim 13 , further comprising the step of drying the crystals of substantially pure crystalline Form I.
15 . The process of claim 9 , wherein the solvent is selected from the group consisting of a protic solvent selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, isobutanol, n-butanol, s-butanol, t-butanol, formic acid, and acetic acid; an aprotic solvent selected from the group consisting of acetone, acetonitrile, dichloromethane, and tetrahydrofuran; and combinations thereof.
16 . The process of claim 15 , wherein the solvent is an alcohol selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, isobutanol, n-butanol, s-butanol, t-butanol, and combinations thereof.
17 . The process of claim 16 , wherein the solvent is ethanol or isopropanol.
18 . The process of claim 9 , wherein the crystalline Form I exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 11.7, about 12.6, about 13.3, about 17.4, about 19.5, about 19.8, and about 21.4.
19 . The process of claim 9 , wherein the crystalline Form I exhibits an endothermic transition with an onset of about 136°-138° C. as measured by differential scanning calorimetry.
20 . A process for preparing a substantially pure hydrous crystalline Form II of sufentanil citrate, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, 2-hydroxy-1,2,3-propanetricarboxylate, the process comprising:
a) contacting sufentanil citrate, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, 2-hydroxy-1,2,3-propanetricarboxylate, with a solvent to form a saturated or a near saturated solution; and
b) forming crystals of substantially pure hydrous crystalline Form II.
21 . The process of claim 20 , wherein the saturated or near saturated solution is heated to about the boiling point of the solvent during step (a).
22 . The process of claim 21 , wherein the crystals are formed by cooling the solution.
23 . The process of claim 20 , further comprising the step of collecting the crystals of substantially pure crystalline Form I.
24 . The process of claim 23 , further comprising the step of drying the crystals of substantially pure crystalline Form I.
25 . The process of claim 20 , wherein the solvent is selected from the group consisting of a protic solvent selected from the group consisting of water, methanol, ethanol, isopropanol, n-propanol, isobutanol, n-butanol, s-butanol, t-butanol, formic acid, and acetic acid; an aprotic solvent selected from the group consisting of acetone, acetonitrile, dichloromethane, and tetrahydrofuran; and combinations thereof.
26 . The process of claim 25 , wherein the solvent is water.
27 . The process of claim 20 , wherein the crystalline Form II exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 5.6, about 10.0, about 11.4, about 13.4, about 19.1, and about 21.2.
28 . The process of claim 20 , wherein the crystalline Form II exhibits an endothermic transition with an onset of about 114°-118° C. as measured by differential scanning calorimetry.